A major challenge in Spinal Dural Arteriovenous Fistula (SDAVF) was its timely diagnosis, but no specific predictive biomarkers were known. In the discovery cohort (case, n=8 vs. control, n=8), we used cerebrospinal fluid (CSF) and paired plasma samples to identify differentially expressed proteins by label-free quantitative proteomics. Further bioinformatics enrichment analyses were performed to screen target proteins. Finally, it was validated by ELISA experiment in two of the new cohort (case, n=17 vs. control, n=9).